{"created":"2023-05-15T14:43:27.962047+00:00","id":231,"links":{},"metadata":{"_buckets":{"deposit":"bc68cac9-2ee9-46bd-9119-980af2f94116"},"_deposit":{"created_by":3,"id":"231","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"231"},"status":"published"},"_oai":{"id":"oai:meigaku.repo.nii.ac.jp:00000231","sets":["49:50:52"]},"author_link":["5425","5424"],"item_2_alternative_title_19":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Japanese firms' competitive advantages in stem cell business"}]},"item_2_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"146","bibliographicPageEnd":"20","bibliographicPageStart":"11","bibliographic_titles":[{"bibliographic_title":"明治学院大学経済研究 = The papers and proceedings of economics"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"再生医療業界の発展は，日本経済に二つのポジ\nティブな影響を与えると考えられる。第一に，日\n本経済の事業構造の転換に貢献し，雇用の創出と\n需給ギャップの是正を通じて，デフレ克服を後押\nしすること。第二に，再生医療によって慢性疾患\nが完治した場合，医療費の圧縮が可能になり，財\n政の再建に寄与する可能性を期待できることであ\nる。ただし，第一の効果を実現するためには，日\n本企業が，再生医療業界において競争優位性を構\n築しなければならない。また，日本企業が高い収\n益を達成すれば，税収の増加による財政再建も期\n待できる。本稿では，既に市場が立ちあがってい\nる創薬プロセスを対象とした幹細胞ビジネスにつ\nいて概観し，再生医療産業における日本企業の競\n争優位性の構築には，国内の基礎研究機関と学際\n的な研究プロジェクトに対し研究費支援を強化し\nていくことと，細胞を用いた医療サービスについ\nて新たな法整備を進めていくことが必要であると\n指摘する。","subitem_description_type":"Abstract"}]},"item_2_description_40":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"明治学院大学経済学部"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA11966517","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_8":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1349-483X","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"貴志, 奈央子"}],"nameIdentifiers":[{"nameIdentifier":"5424","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"KISHI, Naoko"}],"nameIdentifiers":[{"nameIdentifier":"5425","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-03-09"}],"displaytype":"detail","filename":"経済研究_146_11-20.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"経済研究_146_11-20.pdf","url":"https://meigaku.repo.nii.ac.jp/record/231/files/経済研究_146_11-20.pdf"},"version_id":"9796714b-8117-4773-bf8b-9412c3bfd7e3"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"幹細胞ビジネスにおける日本企業の競争優位性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"幹細胞ビジネスにおける日本企業の競争優位性"}]},"item_type_id":"2","owner":"3","path":["52"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-07-11"},"publish_date":"2013-07-11","publish_status":"0","recid":"231","relation_version_is_last":true,"title":["幹細胞ビジネスにおける日本企業の競争優位性"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-05-15T15:50:35.581311+00:00"}